Clinical Trial Update: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study of pevonedistat in combination with ibrutinib for relapsed or refractory chronic lymphocytic leukemia and v…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Lymphoplasmacytic Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma
• Richter Syndrome

Drugs mentioned

• Ibrutinib (ibrutinib)
• Pevonedistat (pevonedistat)

Snippet

Sponsor: City of Hope Medical Center | Conditions: B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING